COVID-19系统生物学揭示新的基因签名在肺和全血
![PPI networks and clusters of lung DEGs. (A) PPI networks of upregulated DEGs emerged from the lung datasets, constructed with the platforms STRING (left) and NetworkAnalyst (right). (B) PPI networks of downregulated DEGs emerged from the lung datasets, constructed with the platforms STRING (left) and NetworkAnalyst (right). (C) Neighborhoods of upregulated DEGs clusters from lung datasets, where proteins are densely connected and corresponding pathways. Constructed with Metascape. (D) Neighborhoods of downregulated DEG clusters from lung datasets, where proteins are densely connected and corresponding pathways. Constructed with Metascape. PPI, protein–protein interaction; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins. Credit: OMICS: A Journal of Integrative Biology (2022). DOI: 10.1089/omi.2022.0104 Covid系统生物学揭示新的基因签名在肺和全血](https://scx1.b-cdn.net/csz/news/800a/2022/covid-systems-biology.jpg)
系统生物学的方法研究的影响SARS-CoV-2病毒在肺癌和全血确定新的COVID-19基因签名,代表了潜在的治疗或诊断目标。这项新研究发表在组学:一个综合生物学》杂志上。
COVID-19是一种全身性疾病影响组织和器官,包括和超越肺。“血是一个很好的指标的整体主机响应,因为它携带免疫细胞整个身体,”这项研究的作者。“联合研究的两个组织可以解开SARS-CoV-2主机响应的复杂性。”
相应的作者教授范吉利斯马诺洛波洛斯和尼古拉斯Dovrolis博士,从色雷斯德谟克利特大学的医学院,在Alexandroupolis合作者,希腊,利用转录组差异表达分析基因在肺样本和整个COVID-19患者和健康人的血液样本。
他们发现了35个差异表达基因之间常见的肺癌和整体血,重要的是,两个基因,即CYP1B1 TNFAIP6,与COVID-19未曾涉及。他们还发现了四个microrna的潜在的监管机构。
“两年多COVID-19大流行,全球与SARS-CoV-2斗争仍在继续。我们的知识的影响COVID-19整个生物体水平仍然有限。在这种背景下,研究显示的价值系统生物学方法解压的病理生理学COVID-19在多个组织。基因签名识别研究中开辟新天地COVID-19药物和诊断发现。我邀请新手稿COVID-19系统生物学和multi-omics研究同行评议的杂志,“DABCP Vural奥兹德米尔说,医学博士,博士,主编组学。
更多信息:Dimitra Anatolou et al,开箱COVID-19系统生物学在肺癌和全血与转录组和microrna的监管机构,组学:一个综合生物学》杂志上(2022)。DOI: 10.1089 / omi.2022.0104